Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Stock Information for Concert Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Concert Pharmaceuticals Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, ISO, TIG
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, AQUA, LPTX, ALR
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, CNCE, AQUA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, ANGN, CNCE
ALERT: The M&A Class Action Firm Continues Investigating the Merger - HZNP, ANGN, TIG, CNCE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.